Selected article for: "BCG vaccination and reduce mortality rate"
Author: Koti, Madhuri; Morales, Alvaro; Graham, Charles H; Siemens, David Robert
Title: BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy
  • Cord-id: jn9qai51
  • Document date: 2020_7_6
    • ID: jn9qai51
    Snippet: The COVID-19 pandemic has killed over 400 000 people globally. Ecological evidence indicates that countries with national universal BCG vaccination programs for tuberculosis (TB) prevention have a much lower incidence of severe COVID-19 and mortality compared with those that do not have such programs. BCG is a century old vaccine used for TB prevention via infant/childhood vaccination in lowto middle-income countries with high infection prevalence rate and is known to reduce all-cause neonatal m
    Document: The COVID-19 pandemic has killed over 400 000 people globally. Ecological evidence indicates that countries with national universal BCG vaccination programs for tuberculosis (TB) prevention have a much lower incidence of severe COVID-19 and mortality compared with those that do not have such programs. BCG is a century old vaccine used for TB prevention via infant/childhood vaccination in lowto middle-income countries with high infection prevalence rate and is known to reduce all-cause neonatal mortality. BCG remains the standard immunotherapy treatment for patients with high-risk non-muscle invasive bladder cancer globally for more than 44 years. Several trials are, therefore, investigating BCG as a prophylactic against COVID-19 in healthcare workers and the elderly. In this commentary, we discuss the potential mechanisms that may underlie BCG associated heterologous protection with a focus on tertiary lymphoid structure (TLS) organogenesis. Given the significance of TLSs in mucosal immunity, their association with positive prognosis and response to immune checkpoint blockade with a critical role of Type I interferon (IFN-1) in inducing these, we also discuss potentiating TLS formation as a promising approach to enhance anti-tumor immunity. We propose that lessons learned from BCG immunotherapy success could be applied to not only augment such microbe-based therapeutics but also lead to similar adjunctive IFN-1 activating approaches to improve response to immune checkpoint blockade therapy in cancer.

    Search related documents:
    Co phrase search for related documents
    • acid inducible and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acid inducible and adaptive immune cell: 1
    • acid inducible and adaptive immune response: 1, 2, 3, 4, 5
    • acid inducible gene and activation induce: 1, 2
    • acid inducible gene and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acid inducible gene and adaptive immune cell: 1
    • acid inducible gene and adaptive immune response: 1, 2, 3, 4, 5
    • activation defect and adaptive immune cell: 1
    • activation induce and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • activation induce and adaptive immune response: 1, 2, 3, 4
    • activation induce and adenoviral vector: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and adaptive immune cell innate: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and adaptive immune response activation: 1, 2
    • acute sars cov respiratory syndrome coronavirus and adaptive immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute sars cov respiratory syndrome coronavirus and adenoviral vector: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and adjunctive treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute sars cov respiratory syndrome coronavirus and local administration: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and long protection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25